Varoglutamstat Inhibits the Dimerization of the Aβ_25-35 Fragment in Aqueous Solution

Area of Science:

• Biochemistry
• Neuroscience
• Computational Chemistry

Background:

• Amyloid-beta (Aβ) peptide self-aggregation is a hallmark of Alzheimer's disease.
• Understanding molecular interactions that inhibit Aβ aggregation is crucial for therapeutic development.

Purpose of the Study:

• To investigate the effect of varoglutamstat on the conformational dynamics of the FAβ25-35 dimer.
• To determine the required simulation length for accurately assessing ligand inhibition of Aβ aggregation.

Main Methods:

• Molecular dynamics (MD) simulations were employed to study the FAβ25-35 dimer.
• Simulations were extended to 20.0 μs to capture long-term ligand effects.
• Analysis focused on conformational changes, intermolecular contacts, and β-content.

Main Results:

• Varoglutamstat reduced nonbonded intermolecular contacts and β-content in the FAβ25-35 dimer.
• Extended MD simulations (20.0 μs) were necessary to fully elucidate the ligand's influence.
• The amyloid-competent dimer structure population significantly decreased with varoglutamstat addition.

Conclusions:

• Varoglutamstat impacts the free energy landscape of the FAβ25-35 dimer, reducing amyloid formation.
• Ligand-induced conformational changes may involve transitions through random coil states.
• Accurate assessment of Aβ inhibitors requires longer MD simulation times than conventionally used.